Aminopurine based JNK inhibitors for the prevention of ischemia reperfusion injury.
Krenitsky, V.P., Delgado, M., Nadolny, L., Sahasrabudhe, K., Ayala, L., Clareen, S.S., Hilgraf, R., Albers, R., Kois, A., Hughes, K., Wright, J., Nowakowski, J., Sudbeck, E., Ghosh, S., Bahmanyar, S., Chamberlain, P., Muir, J., Cathers, B.E., Giegel, D., Xu, L., Celeridad, M., Moghaddam, M., Khatsenko, O., Omholt, P., Katz, J., Pai, S., Fan, R., Tang, Y., Shirley, M.A., Benish, B., Blease, K., Raymon, H., Bhagwat, S., Henderson, I., Cole, A.G., Bennett, B., Satoh, Y.(2012) Bioorg Med Chem Lett 22: 1427-1432
- PubMed: 22226655 
- DOI: 10.1016/j.bmcl.2011.12.028
- Primary Citation of Related Structures:  
3TTJ - PubMed Abstract: 
In this Letter we describe the optimization of an aminopurine lead (1) with modest potency and poor overall kinase selectivity which led to the identification of a series of potent, selective JNK inhibitors. Improvement in kinase selectivity was enabled ...